Get the Stockscreener App
4.015
2.03%
0.065
Anavex Life Sciences Corporation stock is traded at $4.015, with a volume of 2.17M.
It is up +2.03% in the last 24 hours and down -8.41% over the past month.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
See More
Previous Close:
$3.95
Open:
$4.125
24h Volume:
2.17M
Relative Volume:
0.84
Market Cap:
$359.63M
Revenue:
-
Net Income/Loss:
$-48.17M
P/E Ratio:
-7.0439
EPS:
-0.57
Net Cash Flow:
$-37.10M
1W Performance:
+6.05%
1M Performance:
-8.41%
6M Performance:
-62.65%
1Y Performance:
-69.26%
1-Day Range:
$3.985
$4.37
1-Week Range:
$3.495
$4.37
52-Week Range:
$2.86
$14.25
Anavex Life Sciences Corporation Stock (AVXL) Company Profile
Name
Anavex Life Sciences Corporation
Sector
Industry
Phone
844-689-3939
Address
630 5TH AVENUE, NEW YORK
Compare AVXL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVXL
Anavex Life Sciences Corporation
|
4.025 | 352.93M | 0 | -48.17M | -37.10M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.85 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.46 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
405.59 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
801.70 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.74 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Sep-23-21 | Initiated | BTIG Research | Buy |
| Dec-16-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-28-20 | Initiated | Ladenburg Thalmann | Buy |
| Feb-27-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-18-19 | Initiated | Janney | Buy |
| May-16-18 | Resumed | Maxim Group | Buy |
| Mar-08-18 | Initiated | ROTH Capital | Buy |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
| Sep-29-17 | Resumed | Noble Financial | Buy |
| Feb-07-17 | Initiated | Noble Financial | Buy |
| Mar-29-16 | Initiated | FBR Capital | Outperform |
View All
Anavex Life Sciences Corporation Stock (AVXL) Latest News
Anavex Life Sciences (AVXL) Receives Reaffirmed Buy Rating from D. Boral Capital | AVXL Stock News - GuruFocus
D. Boral Capital Reaffirms "Buy" Rating for Anavex Life Sciences (NASDAQ:AVXL) - MarketBeat
Anavex Life Sciences Corp. Invited by FDA to Present Alzheimer’s Disease Clinical Trial Results - Quiver Quantitative
Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program - The Manila Times
FDA takes closer look at experimental Alzheimer’s pill in key meeting - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp.AVXL - PR Newswire
Analyzing 3 Promising Penny Stocks With Market Caps Over $60M - simplywall.st
Anavex Life Sciences (NASDAQ:AVXL) Stock Passes Below 50-Day Moving AverageHere's What Happened - MarketBeat
Will Anavex Life Sciences Corp. stock continue upward momentumDividend Yield Trends & Free Record-Breaking Gains - bollywoodhelpline.com
AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm - GlobeNewswire
What analysts say about Anavex Life Sciences Corp stockHigh Beta Stocks & Maximize ROI With Proven Growth Stocks - earlytimes.in
Anavex asks EMA to re-examine its negative opinion on blarcamesine for Alzheimer's - MSN
Anavex Life Sciences' (AVXL) Buy Rating Reiterated at HC Wainwright - MarketBeat
Can Anavex Life Sciences Corp. stock sustain free cash flow growth2025 Price Targets & Daily Volume Surge Trade Alerts - Улправда
D. Boral Capital Maintains Anavex Life Sciences (AVXL) Buy Recommendation - Nasdaq
Can Anavex Life Sciences Corp. stock resist market sell offs2025 Valuation Update & Weekly Watchlist for Consistent Profits - DonanımHaber
Rate Cut: Why Anavex Life Sciences Corp stock could be next big winner2025 Trading Volume Trends & Accurate Buy Signal Notifications - moha.gov.vn
Why Anavex Life Sciences Corp. stock could rally in 2025Stock Surge & Risk Controlled Swing Trade Alerts - ulpravda.ru
Anavex asks EMA to re-examine its negative opinion on blarcamesine for Alzheimer's. Read more here. - Seeking Alpha
Anavex Life Sciences Requests European Medicines Agency to Re-evaluate Blarcamesine as Early Alzheimer's Treatment - marketscreener.com
What catalysts could drive Anavex Life Sciences Corp. stock higher2025 Institutional Moves & Technical Pattern Recognition Alerts - Улправда
Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion - The Manila Times
Anavex Life Sciences requests EMA to re-examine blarcamesine for Alzheimer's - marketscreener.com
EU regulators asked to revisit an experimental pill for early Alzheimer’s - Stock Titan
Anavex Life Sciences’ (AVXL) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Anavex Life Sciences (AVXL): Analyst Ratings Update for December 15, 2025 | AVXL Stock News - GuruFocus
Anavex Life Sciences (NASDAQ:AVXL) Earns Buy Rating from D. Boral Capital - MarketBeat
EU Rejects Anavex’s Alzheimer’s Drug, But Backs Seven Others - Citeline News & Insights
Anavex Life Sciences (AVXL) Projected to Post Quarterly Earnings on Monday - Defense World
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease - The Manila Times
Anavex Life Sciences Updates on Regulatory Review for Blarcamesine in Treating Early Alzheimer's Disease - Quiver Quantitative
Anavex (NASDAQ: AVXL) to seek CHMP re-exam after EU negative view on blarcamesine - Stock Titan
Anavex Life Sciences (AVXL) Stock Drops After EMA Recommends Refusal of Blarcamesine: Latest News, Analyst Forecasts, and What’s Next (Dec. 12, 2025) - ts2.tech
Anavex (AVXL) Faces EMA Setback on Alzheimer's Drug Application - GuruFocus
How does Anavex Life Sciences Corporation (AVXL) change from a tortoise to a hare? - Setenews
Anavex Life Sciences Reports Q4 2025 Financials and Updates - MSN
Is Anavex Life Sciences Corp. stock a defensive play in 2025Market Risk Analysis & Growth Focused Stock Reports - Newser
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Anavex Life Sciences Corp. (AVXL) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm - Benzinga
Anavex Life Sciences Corp. (AVXL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Marvell Posts Strong Q3 Earnings, Joins American Eagle, Microchip Technology, Box And Other Big Stocks Moving Higher On Wednesday - Benzinga
Anavex Life Sciences Corp. (AVXL) Presents at 18th Clinical Trials on Alzheimer's Disease (CTAD-25) ConferenceSlideshow (NASDAQ:AVXL) 2025-12-03 - Seeking Alpha
Down 50.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Anavex Life Sciences (AVXL) - Finviz
Can Anavex Life Sciences Corp. (12X1) stock sustain institutional flowsMarket Risk Summary & Technical Buy Zone Confirmations - Newser
Bronstein, Gewirtz & Grossman, LLC Is Investigating Anavex Life Sciences Corp. (AVXL) And Encourages Shareholders to Connect - ACCESS Newswire
Check Out Anavex Life Sciences Corporation (AVXL)’s Trade Data Rather Than the Analysts’ Views - Setenews
Anavex Life Sciences Corporation Stock (AVXL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anavex Life Sciences Corporation Stock (AVXL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Thomas Steffen | Director |
Jun 05 '25 |
Option Exercise |
1.76 |
50,000 |
88,000 |
55,000 |
| MISSLING CHRISTOPHER U | President and CEO |
Mar 24 '25 |
Option Exercise |
0.92 |
500,000 |
460,000 |
1,750,210 |
2.45%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):